Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01753713 · ClinicalTrials.gov registry record · Phase 2
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, sponsored by Manmeet Ahluwalia, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01753713 is a Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma that has completed, run by Manmeet Ahluwalia, MD. The registered enrollment target is 33 participants, below the 41-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01753713, a Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, has completed, sponsored by Manmeet Ahluwalia, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well dovitinib works in treating patients with recurrent or progressive glioblastoma. Dovitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG dovitinib
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-12-20 |
| Est. Completion | 2017-09-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01753713
The ClinicalTrials.gov registry entry for NCT01753713 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 41-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (20% lower). The listed sponsor is Manmeet Ahluwalia, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Adult Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01753713 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT01753713 about?
NCT01753713 is a clinical study titled "Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma". This phase II trial studies how well dovitinib works in treating patients with recurrent or progressive glioblastoma. Dovitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
What is the current status of trial NCT01753713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2012-12-20. Estimated completion is 2017-09-20.
What conditions does trial NCT01753713 study?
This clinical trial studies the following conditions: Adult Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor.
What interventions are being tested in trial NCT01753713?
The interventions under investigation include: laboratory biomarker analysis (OTHER), dovitinib (DRUG).
Who is sponsoring clinical trial NCT01753713?
This trial is sponsored by Manmeet Ahluwalia, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01753713 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
COMPLETED · Phase 2
-
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
COMPLETED · Phase 2
-
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
ACTIVE NOT RECRUITING · Phase 1
-
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.